Scancell Holdings plc (AIM:SCLP)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 103.26M |
| Revenue (ttm) | 4.71M |
| Net Income (ttm) | -12.27M |
| Shares Out | 1.04B |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,737,811 |
| Average Volume | 782,708 |
| Open | 9.99 |
| Previous Close | 9.75 |
| Day's Range | 9.70 - 10.20 |
| 52-Week Range | 7.26 - 15.30 |
| Beta | 0.34 |
| RSI | 53.61 |
| Earnings Date | Jan 23, 2026 |
About Scancell Holdings
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targ... [Read more]
Financial Performance
Financial StatementsNews
Scancell Holdings PLC (SCNLF) Full Year 2025 Earnings Call Highlights: Strategic Partnerships ...
Scancell Holdings PLC (SCNLF) Full Year 2025 Earnings Call Highlights: Strategic Partnerships and Financial Resilience Amidst Challenges
Full Year 2025 Scancell Holdings PLC Earnings Call Transcript
Full Year 2025 Scancell Holdings PLC Earnings Call Transcript
Scancell Holdings Plc (SCNLF) Q4 2025 Earnings Call Transcript
Scancell Holdings plc 2025 Q4 - Results - Earnings Call Presentation
Scancell Holdings plc GAAP EPS of -1.26p, revenue of £4.7M
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a b...
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety
PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet and Scancell agreement builds on PharmaJet's strategy to be the best-in-class delivery system for novel DNA and RNA cancer immunotherapies.
PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free
GOLDEN, Colo.--(BUSINESS WIRE)--Positive data announced for first stage of Phase 2 trial for advanced melanoma DNA vaccine delivered by the PharmaJet Stratis needle-free system.